 "Zydus Lifesciences gets USFDA nod for generic drug to treat chest pain")
Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market Nitroglycerin Sublingual tablets, used to treat chest pain, in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) for the drug in strengths of 0.3 mg, 0.4 mg and 0.6 mg, Zydus Lifesciences said in a statement.
Nitroglycerin Sublingual tablets belong to a class of drugs known as nitrates and are used to relieve chest pain (angina) in people who have a certain heart condition (coronary artery disease).
Angina occurs when the heart muscle is not getting enough blood.
The medication works by relaxing and widening blood vessels, so that blood can flow more easily to the heart, the drug firm stated.
The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.
The Zydus group now has 329 approvals and has so far filed over 400 abbreviated new drug approvals (ANDAs) since it commenced the filing process in 2003-04.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app